Core Insights - Fennec Pharmaceuticals has presented new real-world data supporting the use of PEDMARK (sodium thiosulfate injection) in adults with head and neck cancers, indicating its safe administration at least six hours after cisplatin treatment without compromising the drug's antitumor efficacy [1][2][5] - The findings highlight the potential of PEDMARK to mitigate cisplatin-induced hearing loss, a significant survivorship issue, with most high-risk patients showing no measurable hearing loss during or after treatment [1][4][5] Company Overview - Fennec Pharmaceuticals is focused on the commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in cancer patients, having received FDA approval in September 2022 and subsequent approvals in Europe and the UK [22][24] - The company has entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of PEDMARQSI in Europe, the UK, Australia, and New Zealand [23] Industry Context - Cisplatin is widely used in treating solid tumors but is associated with a high incidence of hearing loss, affecting 60-90% of patients depending on treatment parameters [7][8] - The introduction of PEDMARK represents a significant advancement in addressing the long-term quality of life issues faced by cancer survivors due to treatment-induced hearing loss [12][9]

Core Insights - Fennec Pharmaceuticals is initiating a study to evaluate PEDMARK for preventing cisplatin-induced ototoxicity in adult men with stage II-III metastatic testicular germ cell tumors, reflecting a growing clinical interest in addressing hearing loss among cancer patients [1][4]. Company Overview - Fennec Pharmaceuticals is a specialty pharmaceutical company focused on reducing the risk of ototoxicity in cancer patients receiving cisplatin-based chemotherapy. The company has received FDA approval for PEDMARK in September 2022 and European Commission approval in June 2023 [24][25]. Study Details - The investigator-sponsored study by City of Hope will assess the addition of PEDMARK to standard cisplatin chemotherapy to reduce drug-induced ear damage in men with metastatic testicular germ cell tumors. The study is a Phase I trial (NCT07218913) [5][6]. Clinical Context - Cisplatin has significantly improved survival rates for patients with germ cell tumors, but it can lead to permanent hearing loss in up to 80% of survivors, impacting their quality of life [2][8]. The study aims to integrate hearing protection into comprehensive cancer care [4]. Product Information - PEDMARK (sodium thiosulfate injection) is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged one month and older with localized, non-metastatic solid tumors. It is also recommended for adolescent and young adult patients by the National Comprehensive Cancer Network [3][12]. Market Opportunity - Approximately 500,000 patients in the U.S. are diagnosed annually with cancers treatable by platinum-based chemotherapy, highlighting a significant market opportunity for PEDMARK. The incidence of ototoxicity varies between 60-90% depending on treatment specifics [13][9]. Future Collaborations - Multiple other investigator-initiated studies are under review or in advanced stages of contracting, which are expected to strengthen Fennec's clinical and commercial foundation [7].

Core Insights - The study demonstrated that PEDMARK significantly reduces hearing loss in pediatric patients aged 3-18 years receiving cisplatin, with rates of 24% and 16% for hearing loss compared to historical rates of 56-63% in cisplatin-only groups [1][2][4] - PEDMARK did not interfere with the antitumor activity of cisplatin, showing a clinical response rate of approximately 95% [1][3] - The company plans to pursue registration for PEDMARK in Japan and is exploring partnership or licensing opportunities based on these positive results [1][5] Study Details - The STS-J01 clinical trial enrolled 33 patients, including 27 in the primary cohort (ages 3-18) and 6 in exploratory cohorts, focusing on the prevention of cisplatin-induced ototoxicity [6][7] - The primary endpoint was the incidence of hearing impairment at the end of treatment, assessed using ASHA criteria, with secondary endpoints including safety and antitumor efficacy [7] Pharmacokinetics and Safety - Pharmacokinetic analyses indicated no reduction in cisplatin exposure, confirming that PEDMARK does not adversely interact with cisplatin [3] - The study reported over 200 treatment-emergent adverse events, none attributed to PEDMARK, indicating it was well-tolerated [4] Clinical Implications - The findings support the effectiveness of PEDMARK in protecting hearing without compromising the efficacy of cisplatin, addressing a significant unmet medical need in Japan [5] - The results reinforce the global clinical evidence for PEDMARK, demonstrating its protective effect across various settings and tumor types [4] Regulatory and Market Potential - Fennec Pharmaceuticals intends to register PEDMARK in Japan and is seeking licensing opportunities, highlighting the potential for market expansion [1][5] - PEDMARK is the first FDA-approved therapy for reducing cisplatin-induced ototoxicity in pediatric patients, with significant implications for patient quality of life [10][12]